Clinical trials: Inflammatory Skin Disease
Degenerative Disease, Oncology
Comprehensive Segmental Revision System
Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.
- Conditions
- Degenerative Disease, Oncology, Revision Surgery, Trauma
- Trial name
- NCT03270982
- Testing
- Comprehensive SRS Replacement
- Where
- 4 sites in Canada, Denmark and 1 more
- Volunteers
- 105 people
- Sponsor
- Zimmer Biomet
Avascular Necrosis of Hip, Osteoarthritis, Hip
Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral Component
The Zimmer Hip Resurfacing System Post-Market Clinical Follow-up study will examine the safety and efficacy of this device in the young and/or active patient with advanced hip disease.
- Conditions
- Avascular Necrosis of Hip, Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis
- Trial name
- MMC (NCT03681639)
- Testing
- Serum Metal ion levels determined to monitor changes in chromium and cobalt levels
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Zimmer Biomet
Hyperpigmentation, Skin Ageing
Evaluation of the Safety and Tolerability of a Brightening Treatment Paired With a Skincare Regimen
A12-week single-center, open-label, clinical study is being conducted to assess the efficacy and tolerability of the Brightening Treatment paired with a skincare regimen on healthy female subjects aged 20-65 years with…
- Conditions
- Hyperpigmentation, Skin Ageing, Post Inflammatory Hyperpigmentation, Skin Roughness
- Trial name
- NCT07501000
- Testing
- Brightening Treatment
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Revision Skincare
Venous Leg Ulcer
Management of Infection Risk in Non-comparative Trial (MINT)
The URGO2875 dressing is an innovative antimicrobial dressing made of exclusive technologies of TLC-Ag healing matrix and fibres.
- Trial name
- MINT (NCT03670329)
- Testing
- URGO2875
- Volunteers
- 50 people
- Sponsor
- Laboratoires URGO
Rheumatoid Arthritis, Crohn's Disease
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)
This is an observational trial in Rheumatoid Arthritis and Crohn's Disease patients treated with Cimzia aiming to evaluate the risk and incidence of Tuberculosis.
- Trial name
- NCT01577264
- Where
- 45 sites in Russia
- Volunteers
- 199 people
- Sponsor
- UCB Pharma
Lentigo, Solar Lentigo
Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
The goal of this clinical trial is to compare the 3 different prototype of cyto-selective cryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities.
- Conditions
- Lentigo, Solar Lentigo, Post Inflammatory Hyperpigmentation
- Trial name
- CS5_10B (NCT06305897)
- Testing
- CRYONOVE (EC14_4osc), CRYONOVE (EC+05_1osc), CRYONOVE (EC+05_2osc)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cryonove Pharma
Skin Diseases, Metabolic, Skin Care
Safety and Effectiveness Evaluation of the Apotech® Diabetic Body Moisturizer
Safety and effectiveness evaluation of a new moisturizer formulation with antioxidant, anti-inflammatory and anti-microbial effects in the prevention of diabetics dry skin and complications.
- Trial name
- Apotech (NCT03192592)
- Testing
- Body moisturizer
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- ANS Pharma
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- SCULPTURE (NCT01406938)
- Testing
- AIN457 150mg, AIN457 300mg
- Where
- 131 sites in United States, Austria and 14 more
- Volunteers
- 967 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Asthma
A Clinical Study to Evaluate SM17 in Healthy Participants
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants.
- Conditions
- Atopic Dermatitis, Asthma, Inflammatory Bowel Disease
- Trial name
- NCT07466940
- Testing
- SM17
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Acne
Evaluation of Effaclar Duo+M on Acne Lesions in Subjects With Mild to Moderate Acne on Face and Trunk
This single-center, open, non-randomized study aims the efficacy evaluation of Effaclar Duo+M and Effaclar+M Purifying foaming gel on total acne lesion count, pigmented lesions and scars for 6 months in subjects with mild to…
- Trial name
- NCT06463925
- Testing
- acneic participants group
- Where
- Brazil
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Neoplasms, Breast
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study was designed to determine how effective and safe a new investigational drug, lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast cancer.
- Trial name
- NCT00105950
- Testing
- lapatinib
- Where
- 27 sites in United States, Belgium and 6 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis, Atopic Dermatitis (AD)
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Trial name
- INTEGUMENT 3 (NCT07916480)
- Testing
- Roflumilast Cream 0.3%, Vehicle Cream
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune…
- Conditions
- SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07596680
- Testing
- RD06-05 CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or…
- Conditions
- SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
- Trial name
- NCT07193810
- Testing
- CC312
- Where
- China
- Volunteers
- 6 people
- Sponsor
- CytoCares Inc
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with…
- Trial name
- NCT01610596
- Testing
- Halobetasol Propionate Lotion 0.05%
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Therapeutics, Inc.
Respiratory Tract Infections, Urinary Tract Infections
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- SEPSIS-SHIELD (NCT04094818)
- Testing
- TriVerity
- Where
- 26 sites in United States, Greece
- Volunteers
- 1,441 people
- Sponsor
- Inflammatix
Acne Vulgaris
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection.
- Trial name
- NCT01474798
- Testing
- RA-18C3
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC